Stock listing
A1JH3B Stock Price, News, Filings & Events — Egetis Therapeutics Ab
Selected listing: A1JH3B · LSX · EUR · DE
This page tracks Egetis Therapeutics Ab's A1JH3B:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A1JH3B:LSX. A1JH3B:LSX is the stock-level entry point for investors researching Egetis Therapeutics Ab, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A1JH3B:LSX
- Asset type
- Stock
- Market cap
- $332.0M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LSX
- Currency
- EUR
Egetis Therapeutics Ab A1JH3B:LSX stock context
This page tracks Egetis Therapeutics Ab's A1JH3B:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A1JH3B:LSX. A1JH3B:LSX is the stock-level entry point for investors researching Egetis Therapeutics Ab, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Egetis Therapeutics Ab
Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S.
May 5, 2026
Egetis Appoints Tiago Nunes as Chief Medical Officer
April 9, 2026
Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate(R) (tiratricol) for MCT8 Deficiency
March 27, 2026
Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.
March 9, 2026
Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers
March 2, 2026
Egetis Therapeutics Ab earnings calls
Research Egetis Therapeutics Ab
Egetis Therapeutics Ab investor report
Review AI stock analysis and investor report context for A1JH3B:LSX.
Egetis Therapeutics Ab company profile
View the public company page for Egetis Therapeutics Ab on 6ix.
Egetis Therapeutics Ab news
Read company news and market updates connected to Egetis Therapeutics Ab.
Egetis Therapeutics Ab investor events
Find investor webinars, events, and replay context for Egetis Therapeutics Ab.
Alternate listings
EGTX:OMXSTO
SE · SEK
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
0ABW:LSE
GB · SEK
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
PDPHF:OTC
US · USD
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
A1JH3B:LS
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
P0F:FWB
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
EGTXS:AQUISUK
GB · SEK
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
P0F:GETTEX
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
EGTXS:AQUISEU
GB · SEK
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
P0F:MUN
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.
P0F:SWB
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is A1JH3B:LSX.